Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS).

Boyang ZhengMarie HudsonMianbo WangMurray Baronnull null

Published in: Arthritis research & therapy (2020)

Using a composite response measure, immunosuppression was associated with better outcomes at 1 year in a dcSSc cohort. These results provide real-world data that align with clinical trials to support our current use of immunosuppression.

Keyphrases

systemic sclerosis
interstitial lung disease
clinical trial
low grade
randomized controlled trial
type diabetes
adipose tissue
skeletal muscle
machine learning
combination therapy
phase ii
data analysis
double blind